UK markets closed

Biomea Fusion, Inc. (BMEA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.13-0.37 (-3.22%)
At close: 04:00PM EDT
11.13 0.00 (0.00%)
After hours: 04:07PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.50
Bid11.12 x 200
Ask11.22 x 100
Day's range11.06 - 11.62
52-week range8.12 - 43.69
Avg. volume997,554
Market cap400.063M
Beta (5Y monthly)-0.35
PE ratio (TTM)N/A
EPS (TTM)-3.55
Earnings date01 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est54.43
  • GlobeNewswire

    Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

    Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cellsAnnounced initial clinical data from our Phase 2 study (COVALENT-112) in type 1 diabetes from the first two type 1 diabetes patients dosed with BMF-219 and demonstrated ea

  • GlobeNewswire

    Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on May 1, 2024, the compensation committee of Biomea’s board of directors granted 8 new employees non-qualified stock options to purchase an aggregate of 80,250 shares of th

  • GlobeNewswire

    Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

    BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first two type 1 diabetes patients enrolled in COVALENT-112 both demonstrated early signs of clinical activity with improved measures of beta-cell function after initial treatment with BMF-219BMF-219 has been well tolerated by both patientsOpen label portion of Phase II COVALENT-112 study readout of 40 patients with type 1 diabetes dosed for 12 weeks